Related Experiment Video
Updated: May 31, 2026
Identifying the Effects of BRCA1 Mutations on Homologous Recombination using Cells that Express Endogenous Wild-type BRCA1
Published on: February 17, 2011
Finding novel vulnerabilities of hypomorphic BRCA1 alleles
Anne Schreuder1,2, Klaas de Lint3, Hồ Mỹ Phúc Võ1,2
1Department of Human Genetics, Leiden University Medical Center, The Netherlands.
Abstract:
With the recent rise in CRISPR/Cas9-mediated genome-wide synthetic lethality screens, many new synthetic lethal targets have been identified for diseases with underlying genetic causes such as tumours with BRCA1 mutations. Such screens often use full deficiency of a protein to identify novel vulnerabilities. However, patient-derived mutations not only result in full loss of the protein but often also concern missense mutations with hypomorphic phenotypes. Here, we study the genetic vulnerabilities of two previously described hypomorphic BRCA1 missense mutations and compare these to a BRCA1-depleted setting to study whether this affects screening for synthetic lethal interactions. Our research showed that BRCA1I26A mutated cells have very similar vulnerabilities to BRCA1 wild-type cells, confirming its low tumorigenic effect. In contrast, the BRCA1R1699Q mutation induced a more similar phenotype to BRCA1-deficient cells. For this mutation, we also unveiled a unique vulnerability to the loss of NDE1. Specifically in BRCA1R1699Q mutated cells, and not BRCA1-proficient or -deficient cells, NDE1 loss leads to increased genomic instability. Altogether, our findings highlight the importance to differentiate between patient-derived mutations when assessing novel treatment targets.
Insights
Investigating BRCA1 mutations reveals that not all alterations cause the same vulnerabilities. The BRCA1R1699Q mutation uniquely sensitizes cells to NDE1 loss, highlighting the need to consider specific mutations for targeted cancer therapies.
Area of Science:
- Genomics
- Cancer Biology
- Synthetic Lethality
Background:
- CRISPR/Cas9 screens identify synthetic lethal targets for genetic diseases like BRCA1-mutated cancers.
- Patient mutations often cause hypomorphic phenotypes, unlike the full protein deficiency used in screens.
- Understanding these nuances is crucial for effective therapeutic target identification.
Purpose of the Study:
- To investigate the genetic vulnerabilities of two BRCA1 missense mutations.
- To compare these vulnerabilities to a BRCA1-depleted setting.
- To determine if mutation type affects synthetic lethal interaction screening.
Main Methods:
- Utilized CRISPR/Cas9 genome-wide synthetic lethality screens.
- Studied two hypomorphic BRCA1 missense mutations (I26A and R1699Q).
- Compared mutant cells to BRCA1-depleted and wild-type cells.
Main Results:
- BRCA1I26A mutation showed vulnerabilities similar to wild-type BRCA1 cells.
- BRCA1R1699Q mutation exhibited phenotypes resembling BRCA1-deficient cells.
- BRCA1R1699Q cells uniquely displayed vulnerability to NDE1 loss, causing genomic instability.
Conclusions:
- Differentiating between patient-derived BRCA1 mutations is essential for accurate therapeutic target assessment.
- Hypomorphic mutations can present distinct genetic vulnerabilities compared to full deficiency.
- NDE1 loss represents a potential therapeutic target specifically for BRCA1R1699Q-mutated cancers.
More Related Videos
Related Concept Videos
01:16In vitro Mutagenesis
01:16In-vitro Mutagenesis
01:12Loss of Tumor Suppressor Gene Functions
When the tumor suppressor genes develop mutations or are lost, cells start growing out of control, leading to cancer. However, a single functional copy of the tumor suppressor gene is enough for the cells to maintain their normal functions and cell...
01:20Mismatch Repair
The Mutator Protein Family Plays a Key Role in DNA Mismatch Repair
The human genome has more than 3 billion base pairs of DNA per cell. Prior to cell division, that vast amount of genetic...